Kissei Pharmaceutical Co. Ltd
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thr… Read more
Kissei Pharmaceutical Co. Ltd (KSPHF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2019: 0.000x
Based on the latest financial reports, Kissei Pharmaceutical Co. Ltd (KSPHF) has a cash flow conversion efficiency ratio of 0.000x as of June 2019.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($0.00) by net assets ($180.43 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kissei Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Kissei Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kissei Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kissei Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Motorcomm Electronic Technology Co. Ltd. A
SHG:688515
|
N/A |
|
Cofoe Medical Technology Co.Ltd.
SHE:301087
|
N/A |
|
VALNEVA SE SP.ADS/2
F:AYJ0
|
N/A |
|
Guangxi Liuzhou Pharm Co Ltd
SHG:603368
|
0.006x |
|
ORIC PHARMAC.INC.DL-0001
F:4TZ
|
N/A |
|
HEROUX-DEV.
F:5D6
|
N/A |
|
JC Finance & Tax Interconnect Holdings Ltd
SHE:002530
|
0.018x |
|
Mahanagar Gas Limited
NSE:MGL
|
0.003x |
Annual Cash Flow Conversion Efficiency for Kissei Pharmaceutical Co. Ltd (2005–2025)
The table below shows the annual cash flow conversion efficiency of Kissei Pharmaceutical Co. Ltd from 2005 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $210.12 Billion | $6.52 Billion | 0.031x | +509.22% |
| 2024-03-31 | $221.13 Billion | $-1.68 Billion | -0.008x | +99.83% |
| 2023-03-31 | $1.47 Billion | $-6.68 Billion | -4.555x | -592.74% |
| 2022-03-31 | $1.66 Billion | $1.53 Billion | 0.924x | +8098.49% |
| 2021-03-31 | $1.99 Billion | $-23.00 Million | -0.012x | -116.01% |
| 2020-03-31 | $1.79 Billion | $129.07 Million | 0.072x | +107.59% |
| 2019-03-31 | $1.65 Billion | $57.33 Million | 0.035x | -30.84% |
| 2018-03-31 | $1.65 Billion | $83.17 Million | 0.050x | +23.16% |
| 2017-03-31 | $1.42 Billion | $57.82 Million | 0.041x | +12.04% |
| 2016-03-31 | $1.41 Billion | $51.27 Million | 0.036x | -17.61% |
| 2015-03-31 | $150.72 Billion | $6.67 Billion | 0.044x | -47.11% |
| 2014-03-31 | $142.82 Billion | $11.95 Billion | 0.084x | +21.38% |
| 2013-03-31 | $134.78 Billion | $9.29 Billion | 0.069x | +68.48% |
| 2012-03-31 | $123.38 Billion | $5.05 Billion | 0.041x | +8.11% |
| 2011-03-31 | $123.93 Billion | $4.69 Billion | 0.038x | -56.06% |
| 2010-03-31 | $124.22 Billion | $10.70 Billion | 0.086x | -11.95% |
| 2009-03-31 | $118.42 Billion | $11.58 Billion | 0.098x | +84.18% |
| 2008-03-31 | $118.78 Billion | $6.31 Billion | 0.053x | +65.30% |
| 2007-03-31 | $123.23 Billion | $3.96 Billion | 0.032x | +30.00% |
| 2006-03-31 | $124.26 Billion | $3.07 Billion | 0.025x | -34.93% |
| 2005-03-31 | $120.18 Billion | $4.56 Billion | 0.038x | -- |